Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

BIIB122 · DNL151

Small molecule · developed by BIOGEN

Phase 3 Most advanced trial
BIIB Developer
5 Registered trials

What is BIIB122?

BIIB122 (also known as DNL151) is an investigational agent studied in healthy volunteers and in Parkinson disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
DNL151
Drug type
Small molecule
Therapy area
Neurology
Developer
BIOGEN (BIIB)
Also in trials of
DNLI
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05418673 Phase 3 Parkinson Disease Terminated DNLI
NCT06602193 Phase 2 Parkinson Disease Active not recruiting BIIB
NCT05348785 Phase 2 Parkinson Disease Completed BIIB
NCT05119790 Phase 1 Healthy Volunteers Completed DNLI
NCT05005338 Phase 1 Healthy Volunteers Completed DNLI

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy VolunteersParkinson Disease

More from BIOGEN

Dimethyl Fumarate FDA approved Diroximel Fumarate FDA approved Interferon Beta-1A FDA approved Natalizumab FDA approved Nusinersen FDA approved Omaveloxolone FDA approved Tofersen FDA approved Zuranolone FDA approved BIIB115 Phase 1 BIIB144 Phase 1 BIIB147 Phase 1/2 Diranersen Phase 2

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the BIIB page.

Follow BIIB, the company behind BIIB122

See BIIB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BIIB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.